Symphony Limited Board Approves Interim Dividend, Reverses Subsidiary Divestment

Symphony Limited’s board has approved a ₹2 per share interim dividend. In a strategic shift, the board reversed its prior decision to divest or monetize stakes in its wholly-owned subsidiaries, Climate Holdings Pty Ltd (Australia) and IMPCO S. de R.L. de C.V. (Mexico), citing geopolitical factors and macro-economic dynamics. Executive Director Amit Kumar resigned.

Interim Dividend Declared

The board of directors has declared a 3rd interim dividend of ₹2 (100%) per equity share, with a face value of ₹2 each, for the financial year 2025-26. This dividend will be paid to shareholders on or before February 22, 2026.

Divestment/Monetization Process Halted

Symphony Limited will no longer pursue the divestment or monetization of its stakes in Climate Holdings Pty Ltd (Australia) and IMPCO S. de R.L. de C.V. (Mexico). This decision reverses the process initiated on April 12, 2025.

The company cited a rapidly evolving geo-political landscape, shifting macro-economic dynamics, and heightened external uncertainty as key factors. The board believes maintaining a direct presence in these geographies provides a strategic advantage.

Key Financial Results (Q3 2026)

Symphony Limited’s unaudited consolidated financial results reveal a revenue from operations of ₹593 Crores for the quarter ended December 31, 2025. The net profit after tax from continuing operations is ₹91 Crores for the same period. Standalone revenue from operations reached ₹566 Crores, yielding a net profit after tax of ₹99 Crores.

The earnings per share from continuing operations stood at ₹13.21.

Change in Leadership

Mr. Amit Kumar has formally expressed his intention to resign from his position as Executive Director and Group Chief Executive Officer. The board has accepted his resignation and authorized Mr. Achal Bakeri to finalize the effective date for relinquishment of his responsibilities.

Source: BSE

Previous Article

Heritage Foods Logs 8% Topline Growth & Crosses ₹11,000 Million Mark

Next Article

Gland Pharma Strong Q3 FY26 Results, Revenue Up 22%